FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
RegulatoryapprovedKeytrudaKeytruda QlexPadcevPositive
AI Analysis
Summary
The FDA approved pembrolizumab and pembrolizumab with berahyaluronidase alfa-pmph each in combination with enfortumab vedotin-ejfv as neoadjuvant and adjuvant treatment for muscle invasive bladder cancer on July 10, 2026.
Outcome Details
FDA approved pembrolizumab and pembrolizumab with berahyaluronidase alfa-pmph each in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant therapy for muscle invasive bladder cancer
Importance:9/10
Sentiment:
0.90
FDA approvaloncologycombination therapybladder cancerneoadjuvant treatment
Read the original article
Published by FDA Drugs (New Approvals & NDA) on July 10, 2026 2:19 PM